{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Overall Response Rate= Minor response (\\>25%-50% reduction in monoclonal IgM from baseline + Partial Response (\\>50-90% reduction in monoclonal IgM from baseline)+ Complete Response (Disappearance of monoclonal protein by immunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly (confirmed by CT scan), or signs or symptoms attributable to WM. Reconfirmation of the CR status is required at least 6 weeks apart with a second immunofixation.)","groups":[{"description":"bortezomib and rituximab\n\nBortezomib: Once weekly for 3 weeks\n\nRituximab: Intravenously once a week for the first and fourth weeks of a cycle","id":"OG000","title":"Bortezomib and Rituximab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who had received at least one prior line of therapy","reportingStatus":"POSTED","timeFrame":"2 Years","title":"Overall Response Rate of Bortezomib and Rituximab (VR) in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (WM)","type":"PRIMARY","unitOfMeasure":"Participants"}